NEKTAR THERAPEUTICS
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
NKTR$37.78-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
CONDENSED CONSOLI DATED STATEMENTS OF CASH FLOWS
(In thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(85,526) | $(92,475) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash royalty revenue related to the sales of future royalties | (20,992) | (21,635) |
| Non-cash interest expense on liabilities related to the sales of future royalties | 15,148 | 10,368 |
| Loss from equity method investment | 2,069 | 6,847 |
| Stock-based compensation | 6,720 | 7,384 |
| Depreciation and amortization | 307 | 640 |
| Amortization of premiums (discounts), net | (5,233) | (2,193) |
| Changes in operating assets and liabilities: | ||
| Operating leases, net | (6,835) | (5,580) |
| Other assets | (39,884) | (4,973) |
| Accounts payable | 14,121 | 2,886 |
| Accrued expenses | 37 | 3,940 |
| Net cash used in operating activities | (120,068) | (94,791) |
| Cash flows from investing activities: | ||
| Purchases of investments | (987,707) | (43,852) |
| Maturities of investments | 237,920 | 137,892 |
| Purchases of property and equipment | (112) | (39) |
| Payment of transaction costs and working capital adjustment from the sale of the Huntsville manufacturing facility | — | (697) |
| Net cash provided by (used in) investing activities | (749,899) | 93,304 |
| Cash flows from financing activities: | ||
| Proceeds from shares issued under equity compensation plans | 4,933 | 218 |
| Proceeds from underwritten offering, net of underwriting discounts of $50,025 | 783,725 | — |
| Proceeds from at-the-market offering, net of commissions of $3,300 | 106,699 | — |
| Payments of offering costs associated with issuance of common stock and pre-funded warrants | (1,239) | — |
| Net cash provided by financing activities | 894,118 | 218 |
| Effect of foreign exchange rates on cash and cash equivalents | - | 5 |
| Net increase (decrease) in cash and cash equivalents | 24,151 | (1,264) |
| Cash and cash equivalents at beginning of period | 15,116 | 44,252 |
| Cash and cash equivalents at end of period | $39,267 | $42,988 |
| Non-cash financing activities: | ||
| Offering costs associated with issuance of common stock and pre-funded warrants included in accounts payable and accrued expenses | $250 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.